Study of the combination gemcitabine and trastuzumab in the treatment of HER2+metastatic breast cancer

被引：0
|
作者：
Menjon-Beltran, S. [1 ]
Olivencia-Dueso, R. [1 ]
Gonzalez-Jimenez, E. [1 ]
Titos, M. J. [1 ]
机构：
[1] Hosp Univ Virgen Nieves, Unidad Ginecol Oncol, Granada, Spain
来源：
BREAST CANCER RESEARCH | 2007年 / 9卷 / 01期
关键词：
Gemcitabine; Trastuzumab; Clinical Benefit; Stable Disease; Metastatic Breast Cancer;
D O I：
10.1186/bcr1717
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Gemcitabine and trastuzumab in metastatic breast cancer
    O'Shaughnessy, J
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 22 - 26
  • [42] The role of tyrosine kinase inhibitors in the treatment of HER2+metastatic breast cancer
    Le Du, Fanny
    Dieras, Veronqiue
    Curigliano, Giuseppe
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 175 - 189
  • [43] Real-world treatment in patients with HER2+metastatic breast cancer
    Colomer, R.
    Hall, P.
    Szkultecka-Debek, M.
    Bondi, R. C.
    Flinois, A.
    Auziere, S.
    Le Cleac'h, J. Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 197 - 205
  • [44] Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+metastatic breast cancer
    Tang, Shou-Ching
    Capra, Carter Louis
    Ajebo, Germame H.
    Mairs, Simon
    Meza-Junco, Judith
    Hillegass, William B.
    Craft, Barbara S.
    Zhu, Xiaofu
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+metastatic breast cancer
    Ramagopalan, Sreeram, V
    Pisoni, Riccardo
    Zenin, Aleksandr
    Rathore, Lokendra Singh
    Ray, Joshua
    Sammon, Cormac
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 595 - 602
  • [46] The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
    Parsons, Heather
    Ruddy, Kathryn
    Morganti, Stefania
    Smith, Karen
    Attaya, Victoria
    Kallfelz, Eliza
    DeMeo, Michelle
    LaScala, Jamie
    Mertz, Shirley
    Pollastro, Teri
    Spears, Patricia
    Brufsky, Adam
    Dang, Chau
    Dent, Susan
    Elkhanany, Ahmed
    Gwin, WIlliam
    O'Sullivan, Ciara
    Miller, Kathy
    Nunnery, Sara
    Walsh, Elaine
    Storniolo, Anna Maria
    Tolaney, Sara
    Tayob, Nabihah
    Wolff, Antonio
    Winer, Eric
    Rimawi, Mothaffar
    Krop, Ian
    Lin, Nancy
    CANCER RESEARCH, 2024, 84 (09)
  • [47] Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+metastatic breast cancer
    Tang, Shou-Ching
    Capra, Carter L.
    Ajebo, Germame H.
    Meza-Junco, Judith
    Mairs, Simon
    Craft, Barbara S.
    Zhu, Xiaofu
    Maihle, Nita
    Hillegass, William B.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (04) : 909 - 916
  • [48] Survival of patients with HER2+metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER
    Rugo, H.
    Kaufman, P.
    Tan-Chiu, E.
    Ulcickas, Yood M.
    Paik, S.
    Yardley, D.
    Brufsky, A.
    Mayer, M.
    Birkner, M.
    Wang, L.
    Brammer, M.
    Tripathy, D.
    CANCER RESEARCH, 2009, 69 (02) : 245S - 245S
  • [49] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [50] COST-EFFECTIVENESS ANALYSIS OF NOVEL THERAPIES FOR HER2+METASTATIC BREAST CANCER: [FAM-] TRASTUZUMAB DERUXTECAN VERSUS TUCATINIB TRASTUZUMAB AND CAPECITABINE COMBINATION
    Vondeling, G.
    Palaka, E.
    Livings, C.
    Naik, J.
    Sullivan, W.
    VALUE IN HEALTH, 2020, 23 : S433 - S434
12345